Rituximab Therapy for Primary Sjögren’s Syndrome
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune diseases of the connective tissues, characteristic of the presentation of keratoconjunctivitis sicca and xerostomia. A cardinal pathogenetic feature of SS is B-cell hyperactivity, which has invited efforts on optimal B-cell targeted therapy,...
Main Authors: | Yi Han Chen, Xin Yu Wang, Xin Jin, Zi Yang, Jianguang Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.731122/full |
Similar Items
-
Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
by: Anne Bolette Tjensvoll, et al.
Published: (2019-03-01) -
Severe headache in primary Sjögren’s syndrome responded to rituximab
by: Maysoun Kudsi, et al.
Published: (2023-09-01) -
USE OF RITUXIMAB IN PATIENTS WITH SYSTEMIC MANIFESTATIONS OF PRIMARY SJOGREN'S SYNDROME
by: O. A. Logvinenko, et al.
Published: (2014-12-01) -
Pemphigus Foliaceus—Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report
by: Magdalena Kraft, et al.
Published: (2018-11-01) -
Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells
by: Maximilian Webendörfer, et al.
Published: (2021-02-01)